2011
DOI: 10.1001/jama.2011.257
|View full text |Cite
|
Sign up to set email alerts
|

Reporting of Conflicts of Interest in Meta-analyses of Trials of Pharmacological Treatments

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

7
82
0
1

Year Published

2011
2011
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 134 publications
(90 citation statements)
references
References 66 publications
7
82
0
1
Order By: Relevance
“…A study by Roseman and colleagues (8) investigated the prevalence in which meta-analyses published in high-impact medical journals report on funding sources and conflicts of interest of RCTs that they include. They report that in general, meta-analyses rarely report on COI and funding sources, citing that meta-analyses have no obligation in many high-profile journals to report on conflicts of interest of their included studies (8).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…A study by Roseman and colleagues (8) investigated the prevalence in which meta-analyses published in high-impact medical journals report on funding sources and conflicts of interest of RCTs that they include. They report that in general, meta-analyses rarely report on COI and funding sources, citing that meta-analyses have no obligation in many high-profile journals to report on conflicts of interest of their included studies (8).…”
Section: Discussionmentioning
confidence: 99%
“…They report that in general, meta-analyses rarely report on COI and funding sources, citing that meta-analyses have no obligation in many high-profile journals to report on conflicts of interest of their included studies (8). These findings are similar to those of the present study, and indicate that the concern of lack of conflict of interest reporting is not exclusive to the field of dentistry.…”
Section: Discussionmentioning
confidence: 99%
“…Conflict disclosure was at unacceptably low levels in both types of reviews, even though the systematic ones displayed detailed COI notes more often (25% vs 42%; P  < 0.005) (15). Similar inaccurate and biased reporting also takes place in many other areas of clinical medicine, especially when primary data from randomized trials on drug interventions are pooled and processed in systematic reviews and meta-analyses (16,17). As a prime example, of the 151 items published in the Cochrane Database of Systematic Reviews in 2010, only 46 (30%) provided statements on funding sources of the overviewed trials and 16 (11%) on trial author-industry financial ties and employment (17).…”
mentioning
confidence: 87%
“…A recent Cochrane review has shown that pharmaceutical industry-sponsored studies overestimate the efficacy and underestimate the harm of their treatments, even when controlling for methodological biases (Lundh et al 2012). Thus, study funding sources and financial COIs of investigators should be considered as risks of bias (Roseman et al 2011; Roseman et al 2012). …”
Section: Introductionmentioning
confidence: 99%